Updates on bone health in people living with HIV: global impact, prediction tools, and treatment

Purpose of review Osteoporosis and fragility fractures continue to be a concern for aging people living with HIV (PLWH), despite newer antiretroviral (ART) formulations that are associated with reduced bone toxicity. The aim of this review is to evaluate recent literature focusing on estimates of osteoporosis and fractures in various study populations, efficacy of current fracture risk assessment tools, and interventions to improve bone health outcomes. Recent findings Prevalence of low bone mineral density (BMD) remains higher among PLWH globally, with new estimates ranging from 24 to 59%. The FRAX tool underestimates rate of major osteoporotic fractures in PLWH; some studies suggest that modifications can improve accuracy. Bone quality assessments with trabecular bone score may also improve prediction of vertebral fractures in PLWH. Preexposure prophylaxis (PrEP) with TDF/FTC is generally safe for maternal and infant bone health. Denosumab treatment effectively improves bone mass in PLWH. Summary Despite advancements in ART, osteoporosis and fragility fractures remain common among PLWH. There is a need for continued research on development of fracture risk assessment tools including use of clinical data, imaging studies and biomarkers, and implementation of preventive and treatment strategies for at-risk subgroups.